They can because Acadia's team does has a proven record in developing and commercialising medicine
s ….
CVs of some of the Acadia team (Source:
http://www.acadia-pharm.com/ )
Serge Stankovic, M.D., M.S.P.H. - Executive Vice President, Head of R&D
Joined Acadia in November 2015. Background in clinical and academic psychiatry. Over 20 years of executive level experience in drug development and clinical and medical affairs. Built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. Has led teams to achieve approvals of KEPPRA®, FENTORA®, TREANDA® (orphan drug), NUVIGIL® (orphan drug) and ARISTADA®. Formerly Senior VP of Clinical Development and Medical Affairs at Alkermes plc. (2013 to 2015). Prior to Alkermes, was Senior VP and Head of Global Clinical Development for Teva Pharmaceuticals Ltd; Senior VP, Worldwide Clinical Research at Cephalon; Senior VP, Medical Affairs and Clinical Development CNS at Forest Laboratories, Inc. Also held executive positions in research and development at Neurogen Corporation, Johnson and Johnson, and UCB.
Randall Owen, M.D. - Senior Vice President, Clinical Development and CMO
Joined Acadia in January 2016. Formerly VP, U.S. Clinical Affairs at Lundbeck LLC (2010 - 2016), where he led a team of medical experts and scientists that developed drugs across a wide range of neurological and psychiatric disorders, including innovative development programs in schizophrenia, Alzheimer’s disease and stroke. Prior to Lundbeck, was Group Director, Global Clinical Research at Bristol-Myers Squibb Company where he co-led the life-cycle management of Abilify® during a period of product extensions in psychiatric indications in the United States and Europe.
Daryl DeKarske - Senior Vice President, Global Head of Regulatory Affairs
Joined Acadia in February 2017. Brings more than 20 years of experience in the biopharmaceutical industry. Formerly VP and Global Regulatory Therapeutic Area Head of Neurology, Ophthalmology and Oncology Products at Shire plc and led the global regulatory strategy in diverse therapeutic areas of drug and biologic development. Also served at Shire as VP and Global Regulatory Therapeutic Area Head of Renal-Fibrosis, Ophthalmology and Hematology-Oncology Products as well as Therapeutic Area Head for ADHD/CNS Products. Earlier, held regulatory positions at Sanofi-Aventis S.A. and Pharmacia Corp and conducted clinical and nonclinical research for SmithKline Beecham Corporation and Park-Davis and Company.
Michael J. Yang - Executive Vice President, Chief Commercial Officer
Joined Acadia in March 2017. Formerly at Janssen Pharmaceutical Cos of Johnson & Johnson, where he served as President of Janssen Biotech Inc. and was responsible for building Janssen’s U.S. Immunology business, generating more than $8 billion in annual revenues. Began career at Johnson & Johnson in 1997 and held numerous senior commercial positions such as President, CNS where he was responsible for growing the anti-psychotic long-acting therapy portfolio. Broad background of commercialization and general management experience also includes roles as the Worldwide General Manager of the Medical Device companies of Therakos, Inc and Veridex, LLC, where he launched new platforms, expanded global revenues and diversified the product lines. Prior to that, was VP of Sales and Marketing, Oncology at Ortho Biotech Inc.
Jim Daly, Director
Director since January 2016. Mr. Served as Executive VP and Chief Commercial Officer at Incyte Corporation from (2012 -2015), where he was instrumental in re-accelerating the launch of Jakafi® (orphan drug) and driving sustained growth. Prior to Incyte, worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role there, served as Senior VP, North America Commercial Operations, Global Marketing and Commercial Development. Previously, served as VP and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®(orphan drug), Vectibix®, Nplate® (orphan drug), Xgeva® (orphan drug) and Prolia®. Previously, at Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior VP, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®
Edmund P. Harrigan, M.D., Director
Director since November 2015. Served as Senior VP of Worldwide Safety and Regulatory for Pfizer Inc. (2012 - 2015), where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Previous executive leadership roles at Pfizer include Senior VP, Head of Worldwide Business Development; Senior VP, Head of Worldwide Regulatory Affairs and Quality Assurance; VP, Head of Neuroscience and Ophthalmology; VP of Clinical Development, Therapeutic Area Head, CNS and Pain.
Daniel B. Soland, Director
Director since March 2015. Served as CEO of uniQure N.V., a human gene therapy company (2015-2016); Senior VP and COO of ViroPharma (2008-2014); VP and Chief Commercial Officer of ViroPharma (2006-2008). At ViroPharma, managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Served as President, Chiron Vaccines, of Chiron Corporation (2005- 2006) and led the growth of the vaccine business to over $1 billion in sales. Served as President and CEO of Epigenesis Pharmaceuticals (2002-2005). Formerly worked for GSK, in roles including as VP and Director, Worldwide Marketing Operations, GSK Biologicals.
(20min delay)